Affordable Access

Publisher Website

Antidiabetic activity of lipophilic (−)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition

Authors
Journal
Biomedicine & Pharmacotherapy
0753-3322
Publisher
Elsevier
Publication Date
Volume
61
Issue
1
Identifiers
DOI: 10.1016/j.biopha.2006.11.002
Keywords
  • α-Glucosidase Inhibitor
  • Blood Glucose
  • Postprandial Hyperglycemia
Disciplines
  • Biology
  • Chemistry
  • Medicine

Abstract

Abstract (−)-Epigallocatechin-3-gallate (EGCG), a component of catechins, has been shown to reduce blood glucose levels. In the present study, we investigated the antidiabetic activity and its mechanism of lipophilic EGCG derivative (L-EGCGd) in streptozotocin (STZ)-induced diabetic rats. L-EGCGd was chemically modified from traditional hydrophilic EGCG. After 30 days treatment, plasma levels of glucose were significantly reduced by 40.5 ± 7.0% and 17.0 ± 2.8% in groups administered 50 or 25 mg kg −1d −1 L-EGCGd, respectively, as compared with that in the diabetic control group. Lipid metabolites, such as total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDLC) were effectively attenuated by L-EGCGd administration, but plasma HDLC levels did not change significantly. The oral glucose tolerance test (OGTT) greatly revealed the improved ability of glucose tolerance with treatment of L-EGCGd. L-EGCGd only retarded the postprandial rise in blood glucose with sucrose loading but not glucose loading. And activity of α-glucosidase was inhibited by 50% at the concentration of 246.6 μg ml −1 L-EGCGd. As a result, we first demonstrated that the purified form of compound L-EGCGd possessed the hypoglycemic effect under its role of α-glucosidase inhibition, and therefore should be possibly accepted as an alternative oral medication protecting patients against postprandial hyperglycemic toxicity on the treatment of diabetes and its complications.

There are no comments yet on this publication. Be the first to share your thoughts.